Compare Mutual Funds
Risk
Very High
-
Rating
-
-
Min SIP Amount
₹500
-
Expense Ratio
2.78
-
NAV
₹10.70
-
Fund Started
09 Jun 2025
-
Fund Size
₹553.17 Cr
-
Exit Load
Exit Load for units in excess of 10% of the investment,1% will be charged for redemption within 1 year.
-
1 Year
3.76%
-
3 Year
-
-
5 Year
-
-
Equity
98.03%
-
Cash
-0.58%
-
Top 10 Holdings
Sun Pharmaceutical Industries Ltd. | 7.58% |
Lupin Ltd. | 6.56% |
Laurus Labs Ltd. | 6.31% |
Ipca Laboratories Ltd. | 5.80% |
Torrent Pharmaceuticals Ltd. | 5.43% |
Divi's Laboratories Ltd. | 5.35% |
Apollo Hospitals Enterprise Ltd. | 4.87% |
JB Chemicals & Pharmaceuticals Ltd. | 4.57% |
Fortis Healthcare Ltd. | 4.32% |
Astrazeneca Pharma India Ltd. | 3.87% |
-
Name
-
-
Start Date
-
-
Description
The scheme is to provide long-term capital appreciation by investing predominantly in equity and equity related instruments of Pharma and Healthcare companies. The Scheme does not guarantee/indicate any returns.
-
Launch Date
09 Jun 2025
-
